Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis | Zendy

Orlando M. Gutiérrez | Zendy; Michael Mannstadt | Zendy; Tamara Isakova | Zendy; Jose Alejandro RauhHain | Zendy; Hector Tamez | Zendy; Anand Shah | Zendy; Kelsey Smith | Zendy; Hang Lee | Zendy; Ravi Thadhani | Zendy; Harald Jüppner | Zendy; Myles Wolf | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis

Author(s) -

Orlando M. Gutiérrez,

Michael Mannstadt,

Tamara Isakova,

Jose Alejandro RauhHain,

Hector Tamez,

Anand Shah,

Kelsey Smith,

Hang Lee,

Ravi Thadhani,

Harald Jüppner,

Myles Wolf

Publication year - 2008

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0706130

Subject(s) - medicine , fibroblast growth factor 23 , hyperphosphatemia , hazard ratio , hemodialysis , odds ratio , liter , gastroenterology , kidney disease , confidence interval , risk factor , quartile , proportional hazards model , prospective cohort study , endocrinology , urology , parathyroid hormone , calcium

Fibroblast growth factor 23 (FGF-23) is a hormone that increases the rate of urinary excretion of phosphate and inhibits renal production of 1,25-dihydroxyvitamin D, thus helping to mitigate hyperphosphatemia in patients with kidney disease. Hyperphosphatemia and low 1,25-dihydroxyvitamin D levels are associated with mortality among patients with chronic kidney disease, but the effect of the level of FGF-23 on mortality is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research